Home / BusinessFinancial TimesBusinessFinancial Times·Jun 19, 2026·1 min readAbbVie closes in on nearly $11bn deal for biotech Apogee TherapeuticsBuyout comes amid an uptick in biotech dealmaking as Big Pharma seeks to bolster its drug pipelinesView original source — Financial Times ↗ShareCopy linkShare on XShare on FacebookRelated storiesFinancial TimesBusinessJun 9, 2026 · 1 minGSK in talks to buy cancer biotech Nuvalent for more than $9bnFinancial TimesCNBCBusinessJun 9, 2026 · 1 minGSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FTCNBCBloombergBusinessJun 9, 2026 · 1 minGSK Agrees to Buy Nuvalent for $10.6 BillionBloombergMarketWatchBusinessJun 9, 2026 · 1 minGSK just announced its biggest purchase in eight years to rev up cancer portfolio it had previously wound downMarketWatch
Financial TimesBusinessJun 9, 2026 · 1 minGSK in talks to buy cancer biotech Nuvalent for more than $9bnFinancial Times
CNBCBusinessJun 9, 2026 · 1 minGSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FTCNBC
MarketWatchBusinessJun 9, 2026 · 1 minGSK just announced its biggest purchase in eight years to rev up cancer portfolio it had previously wound downMarketWatch